```
? E AU=KLINMAN AND SUPPRESSIVE


Ref    Items  Index-term
E1        11   AU=KLINMALEE, AUNGSIRI
E2        27   AU=KLINMAN
E3         0  *AU=KLINMAN AND SUPPRESSIVE
E4         1   AU=KLINMAN C S
E5       114   AU=KLINMAN D
E6         2   AU=KLINMAN D K
E7       420   AU=KLINMAN D M
E8         1   AU=KLINMAN D M; HOFFMAN S L
E9         4   AU=KLINMAN D R
E10       85   AU=KLINMAN D.
E11       22   AU=KLINMAN D.  M
E12      591   AU=KLINMAN D.M
E13        2   AU=KLINMAN D.R.
E14        3   AU=KLINMAN DA
E15       63   AU=KLINMAN DENNIS
E16        1   AU=KLINMAN DENNIS A
E17      290   AU=KLINMAN DENNIS M
E18        1   AU=KLINMAN DENNIS R
E19      272   AU=KLINMAN DM
E20        1   AU=KLINMAN DN
E21        1   AU=KLINMAN DP
E22        2   AU=KLINMAN DR
E23        1   AU=KLINMAN E
E24        3   AU=KLINMAN E.
E25        2   AU=KLINMAN EVA

Enter P or PAGE for more
? S E1-E25 AND SUPPRESSIVE


                 11   AU=KLINMALEE, AUNGSIRI
                 27   AU=KLINMAN
                  0   AU=KLINMAN AND SUPPRESSIVE
                  1   AU=KLINMAN C S
                114   AU=KLINMAN D
                  2   AU=KLINMAN D K
                420   AU=KLINMAN D M
                  1   AU=KLINMAN D M; HOFFMAN S L
                  4   AU=KLINMAN D R
                 85   AU=KLINMAN D.
                 22   AU=KLINMAN D.  M
                591   AU=KLINMAN D.M
                  2   AU=KLINMAN D.R.
                  3   AU=KLINMAN DA
                 63   AU=KLINMAN DENNIS
                  1   AU=KLINMAN DENNIS A
                290   AU=KLINMAN DENNIS M
                  1   AU=KLINMAN DENNIS R
                272   AU=KLINMAN DM
                  1   AU=KLINMAN DN
                  1   AU=KLINMAN DP
                  2   AU=KLINMAN DR
                  1   AU=KLINMAN E
                  3   AU=KLINMAN E.
                  2   AU=KLINMAN EVA
             200684   SUPPRESSIVE
      S1        140   E1-E25 AND SUPPRESSIVE
```

```
? S S1 AND (LUNG OR RESPIRATORY OR (INFLAMMATION(W)LUNG))


Processing
Processing

Processed  40 of  50 files ...
Processing
Completed processing all files
                140  S1
            4127837  LUNG
            3585311  RESPIRATORY
            2136379  INFLAMMATION
            4127837  LUNG
              14582  INFLAMMATION(W)LUNG
      S2         19  S1 AND (LUNG OR RESPIRATORY OR (INFLAMMATION(W)LUNG))


? E AU=YAMADA, HIROSHI


Ref    Items  Index-term
E1         6  AU=YAMADA, HIROOMI
E2        20  AU=YAMADA, HIROSAKU
E3      2576 *AU=YAMADA, HIROSHI
E4         5  AU=YAMADA, HIROSHI (GIFU UNIV. (JAPAN). FACULTY O
E5         1  AU=YAMADA, HIROSHI (NAGOYA UNIV. (JAPAN). FACULTY
E6         1  AU=YAMADA, HIROSHI (THE TOKYO ELECTRIC POWER CO.,
E7         1  AU=YAMADA, HIROSHI Y
E8         6  AU=YAMADA, HIROSHI Y.
E9         5  AU=YAMADA, HIROSHI.
E10        1  AU=YAMADA, HIROSHI, E-MAIL: MOTOJIMA.GEN@LHD.NIFS
E11        1  AU=YAMADA, HIROSHIA
E12       11  AU=YAMADA, HIROSHIGE
E13        1  AU=YAMADA, HIROSHIGE.
E14        5  AU=YAMADA, HIROSHISA
E15        2  AU=YAMADA, HIROSHL
E16        3  AU=YAMADA, HIROSI
E17        1  AU=YAMADA, HIROSKI
E18       28  AU=YAMADA, HIROSUKE
E19       90  AU=YAMADA, HIROTADA
E20       35  AU=YAMADA, HIROTAKA
E21       57  AU=YAMADA, HIROTAKE
E22        1  AU=YAMADA, HIROTANE
E23       32  AU=YAMADA, HIROTO
E24        4  AU=YAMADA, HIROTOKU
E25       43  AU=YAMADA, HIROTOMO

Enter P or PAGE for more
? S S2


      S3         19  S2


? RD


      S4          8  RD  (unique items)


? T S4/3,K/1-8
```

>>> KWIC option is not available in file(s): 399
Dialog eLink:
4/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2011 The Thomson Corporation. All rights reserved.

0022284522 Biosis No.: 201100323477
Effect of Suppressive Oligodeoxynucleotides on the Development of
Inflammation-Induced Papillomas

Author: Ikeuchi Hidekazu; Kinjo Takeshi; Klinman Dennis M (Reprint)
Author Address: NCI, Canc and Inflammat Program, Bldg 567,Rm 205, Frederick, MD
21702 USA** USA
Author E-mail Address: klinmand@mail.nih.gov
Journal: Cancer Prevention Research 4 (5): p 752-757 MAY 2011 2011
Item Identifier: doi:10.1158/1940-6207.CAPR-10-0290
ISSN: 1940-6207_(print) 1940-6215_(electronic)
Document Type: Article
Record Type: Abstract
Language: English
Effect of Suppressive Oligodeoxynucleotides on the Development of
Inflammation-Induced Papillomas

Author: ... Klinman Dennis M

Abstract: ...reactions in murine models of autoimmunity, pneumonitis, and shock.
This article examines whether treatment with suppressive (Sup) ODN can interfere
with DMBA/TPA-induced inflammation, thereby reducing papilloma formation. Results
indicate...
DESCRIPTORS:
Diseases: ... respiratory system disease
Mesh Terms:

Dialog eLink:
4/3,K/2 (Item 2 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2011 The Thomson Corporation. All rights reserved.

0021304544 Biosis No.: 200900645981
Therapeutic Applications and Mechanisms Underlying the Activity of Immunosuppressive
Oligonucleotides

Book Title: Oligonucleotide Therapeutics
Author: Klinman Dennis M (Reprint); Tross Debbie; Klaschik Sven; Shirota Hidekazu;
Sato Takeshi
Book Author/editor: Rossi JJ (Editor); Gait MJ (Editor); Eckstein F (Editor)
Author Address: NCI, Canc and Inflammat Program, Bldg 567,Rm 205, Frederick, MD
21702 USA** USA
Author E-mail Address: klinmand@mail.nih.gov
Series Title: Annals of the New York Academy of Sciences 1175 p 80-88 2009
Item Identifier: doi:10.1111/j.1749-6632.2009.04970.x
Book Publisher: BLACKWELL PUBLISHING, 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, UK
Conference/Meeting: 4th Annual Meeting of the Oligonucleotide-Therapeutics-Society
Boston, MA, USA October 15 -18, 2008; 20081015
ISSN: 0077-8923_(print) ISBN: 978-1-57331-758-0 (S)
Document Type: Book Chapter; Meeting; Literature Review
Record Type: Abstract
Language: English
Author: Klinman Dennis M..

Abstract: ...variety of Toll-like receptor ligands, polyclonal activators, and antigens. Several mechanisms contribute to the suppressive activity of such ODN. Ongoing microarray studies indicate that suppressive ODN interfere with the phosphorylation of signal transducer and activator of transcription I (STATI) and STAT4, thereby blocking the inflammation mediated by STAT-associated signaling cascades. In animal models, suppressive ODN can be used to prevent or treat diseases characterized by persistent immune activation, including...
DESCRIPTORS:
Diseases: ... respiratory system disease, toxicity
Mesh Terms:

Dialog eLink:
4/3,K/3 (Item 3 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2011 The Thomson Corporation. All rights reserved.

0020533100 Biosis No.: 200800580039
Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation

Author: Sato Takashi; Shimosato Takeshi; Alvord W Gregory; Klinman Dennis M (Reprint)
Author Address: NCI, Expt Immunol Lab, Bldg 567,Room 205, Frederick, MD 21702 USA**USA
Author E-mail Address: klinmand@mail.nih.gov
Journal: Journal of Immunology 180 (11): p 7648-7654 JUN 1 2008 2008
ISSN: 0022-1767
Document Type: Article
Record Type: Abstract
Language: English
Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation

Author: ... Klinman Dennis M

Abstract: ...inflammatory reactions in murine models of autoinumme disease. Based on those findings, the potential of suppressive ODN to prevent acute murine silicosis was examined. In vitro studies indicate that suppressive ODN blunt silica-induced macrophage toxicity. This effect was associated with a reduction in ROS...
...subunit of NADPH oxidase key to ROS generation). In vivo studies show that pretreatment with suppressive (but not control) ODN reduces silicadependent pulmonary inflammation, as manifest by fewer infiltrating cells, less...
...chemokine production, and lower levels of ROS ($p < 0.01$ for all parameters). Treatment with suppressive ODN also reduced disease severity and improved the survival ($p < 0.05$) of mice exposed...
DESCRIPTORS:
Major Concepts: ... Respiratory System
Biosystematic Names:
Organisms: Parts Etc: lung --... ... respiratory system
Common Taxonomic Terms:
Diseases: ... respiratory system disease, toxicity
Mesh Terms:

Dialog eLink:
4/3,K/4 (Item 1 from file: 34)
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci
(c) 2011 The Thomson Corp. All rights reserved.

18367117 Genuine Article#: 354KW No. References: 87
Title: Synthetic oligonucleotides as modulators of inflammation

Author: Klinman D (REPRINT) ; Shirota H; Tross D; Sato T; Klaschik S
Corporate Source: NCI,Canc & Inflammat Program,Bldg 567,Rm 205/Frederick//MD/21702 (REPRINT); NCI,Canc & Inflammat Program,Frederick//MD/21702
Journal: JOURNAL OF LEUKOCYTE BIOLOGY , 2008 , V 84 , N4 (OCT 1) , P 958-964
ISSN: 0741-5400 Publication Date: 20081001
Publisher: FEDERATION AMER SOC EXP BIOL , 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Author: Klinman D (REPRINT) ; Shirota H; Tross D; Sato T; Klaschik S
Abstract: ...self-DNA, down-regulating the production of proinflammatory and Th1 cytokines. Preclinical studies suggest that " suppressive " ODN may slow or prevent diseases characterized by pathologic immune stimulation, including autoimmunity and septic...
Descriptors: ...CpG ; suppressive ; ODN ; cancer ; therapy
Identifiers: ...PLASMACYTOID DENDRITIC CELLS; INDUCED IMMUNE ACTIVATION; CPG-CONTAINING OLIGODEOXYNUCLEOTIDES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ALLERGIC LUNG INFLAMMATION; 4TH INTERNATIONAL WORKSHOP; COLLAGEN-INDUCED ARTHRITIS; LICENSED ANTHRAX VACCINE; BACTERIAL-DNA; SUPPRESSIVE OLIGODEOXYNUCLEOTIDES
Research Fronts:

Dialog eLink:
4/3,K/5 (Item 2 from file: 34)
DIALOG(R)File 34: SciSearch(R) Cited Ref Sci
(c) 2011 The Thomson Corp. All rights reserved.

13293335 Genuine Article#: 865HH No. References: 30
Title: Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung
Author: Yamada H (REPRINT) ; Ishii KJ; Klinman DM
Author Email Address: hyamada@ob.mbn.or.jp
Corporate Source: Yokohama City Univ,Sch Med, Dept Anesthesiol, Kanazawa Ku,3-9 Fukuura/Yokohama/Kanagawa 2360004/Japan/ (REPRINT); Yokohama City Univ,Sch Med, Dept Anesthesiol, Kanazawa Ku,Yokohama/Kanagawa 2360004/Japan/; Osaka Univ,Akira Innate Immun Project, ERATO,Res Inst Microbial Dis, Japan Sci & Technol A,Osaka//Japan/; US FDA,Sect Retroviral Immunol, Ctr Biol Evaluat & Res,Rockville//MD/20857
Journal: CRITICAL CARE MEDICINE , 2004 , V 32 , N10 (OCT) , P 2045-2049
ISSN: 0090-3493 Publication Date: 20041000
Publisher: LIPPINCOTT WILLIAMS & WILKINS , 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Title: Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung
Author: Yamada H (REPRINT) ; Ishii KJ; Klinman DM
Abstract: Objective: To examine the effect of suppressive oligodeoxynucleotides (ODNs) on the pulmonary inflammation induced by immunostimulatory CpG DNA.

Design: Prospective, randomized, controlled... ...264.7 cells were incubated with bacterial DNA or CpG ODN, alone or combined with suppressive ODN. The in vivo effect of suppressive ODN was determined using an acute lung injury model. CpG ODN alone or combined with suppressive ODN was instilled into the mouse lung .

Measurements and Main Results: Production of tumor necrosis factor (TNF)-alpha and macrophage inflammatory protein... ...the ability of bacterial DNA to stimulate the production of TNF-alpha and MIP-2. Suppressive ODN significantly inhibited the activation of RAW264.7 cells by both bacterial DNA and CpG ODN. In the lung injury model, production of proinflammatory cytokines (TNF-alpha and IL-6) and chemokines (MIP-2... ...of normal mice triggered the synthesis of TNF-alpha, IL-6, MIP-2, and KC. Suppressive ODN significantly blocked the production of these proinflammatory cytokines and chemokines and also reduced neutrophil... ...DNA.

Conclusions. Proinflammatory cytokines and chemokines are up-regulated by CpG motifs in bacterial DNA. Suppressive ODN significantly inhibits the inflammatory response induced by CpG DNA in murine macrophages and the lung . This study supports the use of suppressive ODN to reduce the deleterious inflammatory responses induced by bacterial DNA.
Descriptors: ...CpG motif ; bacterial DNA ; lung ; tumor necrosis factor-alpha ; macrophage inflammatory protein-2

Dialog eLink:
4/3,K/6 (Item 1 from file: 357)
DIALOG(R)File 357: Derwent Biotech Res.
(c) 2011 Thomson Reuters. All rights reserved.

0476036 DBA Accession No.: 2010-07307 PATENT
Treating, preventing or delaying development of tumor in subject, involves selecting subject with tumor or at risk for developing tumor, and administering suppressive oligodeoxynucleotide effective to inhibit inflammation to subject pharmaceutical composition comprising suppressive oligodeoxynucleotide, useful for the treatment of esophagus cancer, stomach carcinoma, lung carcinoma, liver cancer, skin cancer, colon carcinoma and squamous cell carcinoma

Author: IKEUCHI H; KLINMAN D M
Patent Assignee: US DEPT HEALTH and HUMAN SERVICES 2010
Patent Number: US 20100144839 Patent Date: 20100610 WPI Accession No.: 2010-G50142 (201041)
Priority Application Number: US 119998 Application Date: 20081204
National Application Number: US 630315 Application Date: 20091203
Language: English
...in subject, involves selecting subject with tumor or at risk for developing tumor, and administering suppressive oligodeoxynucleotide effective to inhibit inflammation to subject pharmaceutical composition comprising suppressive oligodeoxynucleotide, useful for the treatment of esophagus cancer, stomach carcinoma, lung carcinoma, liver cancer, skin cancer, colon carcinoma and squamous cell carcinoma
Author: IKEUCHI H; KLINMAN D M
Abstract: ...a tumor or at risk for developing a tumor, and administering to the subject a suppressive oligodeoxynucleotide (ODN) effective to inhibit inflammation, where the suppressive ODN is at least 8 nucleotides in length, forms G-tetrad, has CD value of... ...tumor, which involves selecting a subject who has been exposed to a carcinogen and administering suppressive ODN to the subject. BIOTECHNOLOGY - Preferred Method: The ODN has CD value of 3-3... ...preventing, delaying or reducing the risk of developing tumor e.g. malignant tumor, esophageal, stomach, lung , liver, skin or colon tumor benign tumor, where the benign tumor is papilloma and skin cancer is basal cell carcinoma or squamous cell carcinoma (all claimed). ADMINISTRATION - The suppressive ODN is administered systemically or locally at a dosage of 0.01 mg-1 g...
E.C. Numbers:
Descriptors: pharmaceutical comp., suppressive oligodeoxynucleotide, appl., esophagus cancer, stomach carcinoma, lung carcinoma, liver cancer, skin cancer, colon carcinoma, squamous cell carcinoma therapy DNA sequence cytostatic tumor...

Dialog eLink:
4/3,K/7 (Item 2 from file: 357)
DIALOG(R)File 357: Derwent Biotech Res.
(c) 2011 Thomson Reuters. All rights reserved.

0468636 DBA Accession No.: 2009-13840 PATENT
Inhibiting pneumoconiosis in a subject by administering to the subject having pneumoconiosis or at risk of developing pneumoconiosis an amount of a suppressive

oligodeoxynucleotide to inhibit pulmonary inflammation therapeutic composition comprising suppressive oligodeoxynucleotide, useful in treatment of pneumoconiosis and pulmonary inflammation

Author: KLINMAN D M; SATO T
Patent Assignee: US DEPT HEALTHandHUMAN SERVICES 2009
Patent Number: WO 2009143292 Patent Date: 20091126 WPI Accession No.: 2009-R63275 (200981)
Priority Application Number: US 55102 Application Date: 20080521
National Application Number: WO 2009US44739 Application Date: 20090520
Language: English
...to the subject having pneumoconiosis or at risk of developing pneumoconiosis an amount of a suppressive oligodeoxynucleotide to inhibit pulmonary inflammation therapeutic composition comprising suppressive oligodeoxynucleotide, useful in treatment of pneumoconiosis and pulmonary inflammation
Author: KLINMAN D M; SATO T
Abstract: ...to the subject having pneumoconiosis or at risk of developing pneumoconiosis an amount of a suppressive oligodeoxynucleotide to inhibit pulmonary inflammation induced by particle inhalation, where the suppressive oligodeoxynucleotide is 8-40 nucleotides in length, has a CD value of greater than 2... ...of SEQ ID NO. 2. BIOTECHNOLOGY - Preferred Method: In inhibiting pneumoconiosis in a subject, the suppressive oligodeoxynucleotide is administered to an individual at risk of pneumonoconiosis due to an occupational exposure... ...method further comprises detecting the presence of macrophages in a sample from the subject. ACTIVITY - Respiratory -Gen; Antiinflammatory. Test details are described but no results given. MECHANISM OF ACTION - Leukotriene-Antagonist... ...asbestosis in a subject, and reducing the risk of developing silicosis in a subject. The suppressive oligodeoxynucleotide is useful for the treatment of a subject having pneumoconiosis due to an exposure...
E.C. Numbers:
Descriptors: therapeutic comp., suppressive oligodeoxynucleotide, appl., pneumoconiosis, pulmonary inflammation therapy DNA sequence antiinflammatory (28, 200952)
Section: ...DISEASE- Respiratory System

Dialog eLink:
4/3,K/8 (Item 3 from file: 357)
DIALOG(R)File 357: Derwent Biotech Res.
(c) 2011 Thomson Reuters. All rights reserved.

0347503 DBA Accession No.: 2004-19795 PATENT
Use of a suppressive oligodeoxynucleotide for treating or inhibiting inflammatory lung disease such as pneumonia, respiratory distress of prematurity, chronic bronchitis, particularly acute respiratory distress syndrome method of inflammatory lung disease gene therapy using antisense DNA

Author: KLINMAN D M; YAMADA H
Patent Assignee: US DEPT HEALTH and HUMAN SERVICES 2004
Patent Number: US 20040132682 Patent Date: 20040708 WPI Accession No.: 2004-517034 (200449)
Priority Application Number: US 682130 Application Date: 20031007
National Application Number: US 682130 Application Date: 20031007
Language: English
Use of a suppressive oligodeoxynucleotide for treating or inhibiting inflammatory lung disease such as pneumonia, respiratory distress of prematurity, chronic bronchitis, particularly acute respiratory distress syndrome method of inflammatory lung disease gene therapy using antisense DNA
Author: KLINMAN D M; YAMADA H
Abstract: DERWENT ABSTRACT: NOVELTY - Treating or inhibiting inflammatory lung disease, reducing the production of a cytokine or chemokine, or reducing the infiltration of neutrophils in a tissue in a subject having or at risk of developing

inflammation lung disease comprises administering a suppressive oligodeoxynucleotide which is at least 8 nucleotides in length, forms a G-tetrad, has a... ...9, and comprises at least two guanosines. BIOTECHNOLOGY - Preferred Method: In treating or inhibiting inflammatory lung disease, the disease is acute respiratory distress syndrome, pneumonia, respiratory distress of prematurity, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis or pulmonary sarcoidosis, preferably acute respiratory distress syndrome. The oligodeoxynucleotide has a CD value of greater than 3.0 or 3... ...production of a cytokine or chemokine in a cell comprises contacting the cell with a suppressive oligodeoxynucleotide defined above. The cell is a macrophage. The cytokine or chemokine is tumor necrosis... ...protein 2 or keratinocyte-derived cytokine. The method can alternatively be done by administering the suppressive oligodeoxynucleotide described above to a subject, thus reducing the production of a cytokine or chemokine in the subject. The subject has or is at risk of developing inflammatory lung disease described above. Reducing the infiltration of neutrophils in a tissue in a subject comprises administering to the subject a suppressive oligodeoxynucleotide described above, thus reducing the infiltration of neutrophils in the tissue. ACTIVITY - Respiratory -Gen.; Antiinflammatory; CNS-Gen. MECHANISM OF ACTION - Antisense Therapy. An equimolar concentration of suppressive oligodeoxynucleotide was added to CpG-stimulated RAW 246.7 cells. The production of the pro... ...was specific, as control oligodeoxynucleotide had no effect or CpG-induced activation. The effect of suppressive oligodeoxynucleotide on CpG-induced mRNA induction was evaluated by RT-PCR. After 4 hours of... ...chemokine mRNA levels were significantly increased by CpG oligodeoxynucleotide. This effect was significantly blocked by suppressive (but not control) oligodeoxynucleotide. USE - The method is useful for treating or inhibiting inflammatory lung disease, reducing the production of a cytokine or chemokine or reducing the infiltration of neutrophils in a tissue in a subject having or at risk of developing inflammatory lung disease such as acute respiratory distress syndrome, pneumonia, respiratory distress of prematurity, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis or pulmonary sarcoidosis, particularly acute respiratory distress syndrome (claimed). ADMINISTRATION - Administration can be done parenterally, orally, intravenously, intramuscularly, subcutaneously, intranasally, intratracheally...

E.C. Numbers:

Descriptors: ...expression, inhibition, antisense DNA, G tetrad, circular dichroism value effect, neutrophil infiltration reduction, appl., inflammatory lung disease, acute respiratory distress syndrome, pneumonia, repspiratory distress of prematurity, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis...

Section: ...GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; DISEASE- Respiratory System..

```
? DS


Set      Items   Description
S1         140   E1-E25 AND SUPPRESSIVE
S2          19   S1 AND (LUNG OR RESPIRATORY OR (INFLAMMATION(W)LUNG))
S3          19   S2
S4           8   RD  (unique items)


? E AU=YAMADA, HIROSHI


Ref    Items  Index-term
E1         6  AU=YAMADA, HIROOM
E2        20  AU=YAMADA, HIROSAKU
E3      2576 *AU=YAMADA, HIROSHI
E4         5  AU=YAMADA, HIROSHI (GIFU UNIV. (JAPAN). FACULTY O
E5          1   AU=YAMADA, HIROSHI (NAGOYA UNIV. (JAPAN). FACULTY
E6          1   AU=YAMADA, HIROSHI (THE TOKYO ELECTRIC POWER CO.,
E7          1   AU=YAMADA, HIROSHI Y
E8          6   AU=YAMADA, HIROSHI Y.
E9          5   AU=YAMADA, HIROSHI.
E10         1   AU=YAMADA, HIROSHI, E-MAIL: MOTOJIMA.GEN@LHD.NIFS
E11         1   AU=YAMADA, HIROSHIA
E12        11   AU=YAMADA, HIROSHIGE
E13         1   AU=YAMADA, HIROSHIGE.
E14         5   AU=YAMADA, HIROSHISA
E15         2   AU=YAMADA, HIROSHL
E16         3   AU=YAMADA, HIROSI
E17         1   AU=YAMADA, HIROSKI
E18        28   AU=YAMADA, HIROSUKE
E19        90   AU=YAMADA, HIROTADA
E20        35   AU=YAMADA, HIROTAKA
E21        57   AU=YAMADA, HIROTAKE
E22         1   AU=YAMADA, HIROTANE
E23        32   AU=YAMADA, HIROTO
E24         4   AU=YAMADA, HIROTOKU
E25        43   AU=YAMADA, HIROTOMO

Enter P or PAGE for more
? S E1-E25


               6   AU=YAMADA, HIROOMI
              20   AU=YAMADA, HIROSAKU
            2576   AU=YAMADA, HIROSHI
               5   AU=YAMADA, HIROSHI (GIFU UNIV. (JAPAN). FACULTY O
               1   AU=YAMADA, HIROSHI (NAGOYA UNIV. (JAPAN). FACULTY
               1   AU=YAMADA, HIROSHI (THE TOKYO ELECTRIC POWER CO.,
               1   AU=YAMADA, HIROSHI Y
               6   AU=YAMADA, HIROSHI Y.
               5   AU=YAMADA, HIROSHI.
               1   AU=YAMADA, HIROSHI, E-MAIL: MOTOJIMA.GEN@LHD.NIFS
               1   AU=YAMADA, HIROSHIA
              11   AU=YAMADA, HIROSHIGE
               1   AU=YAMADA, HIROSHIGE.
               5   AU=YAMADA, HIROSHISA
               2   AU=YAMADA, HIROSHL
               3   AU=YAMADA, HIROSI
               1   AU=YAMADA, HIROSKI
              28   AU=YAMADA, HIROSUKE
              90   AU=YAMADA, HIROTADA
              35   AU=YAMADA, HIROTAKA
              57   AU=YAMADA, HIROTAKE
               1   AU=YAMADA, HIROTANE
              32   AU=YAMADA, HIROTO
               4   AU=YAMADA, HIROTOKU
              43   AU=YAMADA, HIROTOMO
      S5    2936   E1-E25

? S S5 AND (SUPPRESSIVE AND (LUNG OR RESPIRATORY))


            2936   S5
          200684   SUPPRESSIVE
         4127837   LUNG
         3585311   RESPIRATORY
      S6       2   S5 AND (SUPPRESSIVE AND (LUNG OR RESPIRATORY))
```

```
? RD


     S7         2  RD  (unique items)


? T S7/3,K/1-2


>>> KWIC option is not available in file(s): 399
Dialog eLink:
7/3,K/1 (Item 1 from file: 399)
DIALOG(R)File 399: CA SEARCH(R)
(c) 2011 American Chemical Society. All rights reserved.


142091829        CA: 142(6)91829s          JOURNAL
Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung

Author: Yamada, Hiroshi; Ishii, Ken J.; Klinman, Dennis M.
Location: Department of Anesthesiology, Yokohama City University, School of
Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan, 236-0004
Journal: Crit. Care Med.
Date: 2004
Volume: 32 Number: 10 Pages: 2045-2049
CODEN: CCMDC7
ISSN: 0090-3493
Language: English
Publisher: Lippincott Williams & Wilkins



Dialog eLink:
7/3,K/2 (Item 2 from file: 399)
DIALOG(R)File 399: CA SEARCH(R)
(c) 2011 American Chemical Society. All rights reserved.


141082332        CA: 141(6)82332b          PATENT
Method of treating inflammatory lung disease with suppressors of CpG
oligonucleotides
Inventor (Author): Klinman, Dennis M.; Yamada, Hiroshi
Location: USA
Assignee: The Government of the U.S.A. as Represented by the Secretary of the
Dept.of Health & Human Services
Patent: U.S. Pat. Appl. Publ. ; US 20040132682 A1      Date: 20040708
Application: US 682130 (20031007) *US PV417263 (20021008)
Pages: 29 pp.
CODEN: USXXCO
Language: English
Patent Classifications:
  Class:    514044000; A61K-048/00A



? DS


Set     Items   Description
S1        140   E1-E25 AND SUPPRESSIVE
S2         19   S1 AND (LUNG OR RESPIRATORY OR (INFLAMMATION(W)LUNG))
S3         19   S2
```

```
S4            8    RD  (unique items)
S5         2936    E1-E25
S6            2    S5 AND (SUPPRESSIVE AND (LUNG OR RESPIRATORY))
S7            2    RD  (unique items)
```